George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn:
“Excellent Review
“Beyond Borders: Ag(e)nostic Therapies Reshape Cancer Treatment”
Ag(e)nostic precision oncology therapy approvals across the years
Ag(e)nostic Cancer Therapies: The Future of Precision Oncology
Precision oncology treatments, which target specific genetic mutations in tumors, are typically approved for use in adults with a particular type of cancer and a specific genetic biomarker. However, a new class of treatments called ag(e)nostic therapies is changing this model.
These therapies are approved for all ages and are not restricted to a specific tumor type. This is particularly important for patients with rare cancers, especially children, as finding enough patients for a clinical trial for a rare biomarker in an already rare cancer is extremely difficult.
The authors of this paper argue that these ag(e)nostic approvals should become the standard for precision oncology drugs. By making these therapies available to a wider range of patients, they can better meet the needs of those with rare and ultra-rare malignancies. This approach represents a significant step forward in making highly effective treatments accessible to more people.
Figure Courtesy: Trends in Cancer.”
Title: Ag(e)nostic precision oncology therapy approvals across the years
Authors: Matthew R. Kudek, Jacob J. Adashek, Razelle Kurzrock
Read the Full Article.
More posts featuring George Kumar.
